drug
as of 2026-07-01Melatonin
MeSH D008550
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Beijing HuiLongGuan Hospital
6 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
SchizophreniaSchizophrenia DisordersDepressionPsychosomatic DisordersDiabetes MellitusBipolar Affective DisorderBipolar DisorderSchizophreniaAnxiety DisordersSecond Generation Antipsychotic Induced Metabolic Adverse EffectsDepressionTardive DyskinesiaWeight GainPsychotic DisorderHyperglycemiaPsychotic Disorders
Trials
6
Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial
NCT06838104—Active Not Recruiting
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567Phase 3Terminated
Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia
NCT01431092Phase 4Completed
Melatonin for Prevention of Metabolic Side Effects of Olanzapine
NCT01593774Phase 2Completed
Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics
NCT01811160Phase 4Completed
Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
NCT01391390—Completed
KOLs & investigators
7
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
trial
indication
indication
indication
indication
indication
KOL
Birte Glenthøj, Professor
personKOL score 19
Lone Baandrup, MD, PhD
personKOL score 7
Helge Frieling, Prof., MD
personKOL score 5
Muhammad Irfan Jamil
personKOL score —